A股異動 | 九洲藥業(603456.SH)漲7.4% 績後獲券商看好
格隆匯10月26日丨九洲藥業(603456.SH)股價持續拉昇,現報39.18元,漲幅7.4%,總市值326.86億。公司2022年第三季度營業收入14.18億元,同比增長24.83%;歸屬於上市公司股東的淨利潤2.75億元,同比增長38.77%。東吳證券指,公司Q3業績環比加速,盈利能力不斷提升。維持公司2022-2024年歸母淨利潤預期的9.7/12.6/16.4億元,2022-2024年對應PE估值分別爲31X、24X、19X;考慮到公司CDMO業績持續釋放,並受益於與諾華、Teva等大藥企的深入合作,維持“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.